Table 5.
Sensitivity and specificity of the individual CpG units methylation of genes associated with recurrence of cancer
| CpG Unit | t-Test (p Value) | Sensitivity (95 %Confidence Interval) | Specificity (95% Confidence Interval) |
|---|---|---|---|
| All recurrence prediction | |||
| FLNC_CpG_20 | .01112 | 71.43 (41.92–91.61) | 68.75 (41.34–88.98) |
| FLNC_CpG_1.2 | .01179 | 71.43 (41.92–91.61) | 68.75 (41.34–88.98) |
| FLNC_CpG_33 | .01179 | 78.57 (49.22–95.34) | 75.06 (47.62–92.73) |
| FLNC_CpG_8 | .01179 | 78.57 (49.20–95.34) | 75.12 (47.62–92.73) |
| FLNC_CpG_21.22 | .01542 | 64.29 (35.14–87.24) | 68.75 (41.34–88.98) |
| GSTP1_CpG_9 | .01649 | 75.02 (42.81–94.51) | 72.73 (39.03–93.98) |
| PITX2_CpG_10 | .01866 | 66.67 (38.38–88.18) | 64.29 (51.42–87.24) |
| GSTP1_CpG_21 | .01923 | 73.33 (44.90–92.21) | 72.73 (39.03–93.98) |
| GSTP1_CpG_19 | .01969 | 76.92 (46.19–94.96) | 81.82 (48.22–97.72) |
| FLNC_CpG_15.16.17 | .02248 | 71.43 (41.90–91.61) | 62.52 (35.43–84.84) |
| EFS_CpG_35 | .02338 | 62.50 (24.49–91.48) | 60.02 (32.29–83.66) |
| Local recurrence prediction | |||
| FLNC_CpG_15.16.17 | .00761 | 77.78 (39.99–97.19) | 78.12 (60.03–90.72) |
| FLNC_CpG_20 | .0114 | 77.78 (39.99–97.19) | 81.25 (63.56–92.79) |
| FLNC_CpG_33 | .01249 | 77.78 (39.99–97.19) | 75.04 (56.62–88.54) |
| FLNC_CpG_8 | .01249 | 77.78 (39.99–97.19) | 75.04 (56.63–88.54) |
| FLNC_CpG_1.2 | .01759 | 77.78 (39.99–97.19) | 81.25 (63.56–92.79) |
| FLNC_CpG_21.22 | .03588 | 77.78 (39.99–97.19) | 75.13 (56.62–88.54) |
| FLNC_CpG_39.40 | .04213 | 77.78 (39.99–97.19) | 78.12 (60.03–90.72) |
| FLNC_CpG_9.10.11 | .04213 | 77.78 (39.99–97.19) | 78.12 (60.03–90.72) |
| PITX2_CpG_36 | .04314 | 70.04 (34.75–93.33) | 70.12 (50.64–85.27) |
| Systemic recurrence prediction | |||
| FLNC_CpG_1.2 | .01762 | 72.73 (39.03–93.98) | 68.75 (49.99–83.88) |
| EFS_CpG_35 | .03987 | 72.73 (39.03–93.98) | 60.14 (40.64–77.34) |
| PSA recurrence prediction | |||
| PDLIM4_02_CpG_1 | .00055 | 20.04 (2.52–55.61) | 42.86 (24.46–62.82) |
| EFS_001_CpG_35 | .01324 | 75.02 (34.91–96.81) | 70.22 (50.62–85.27) |
| KCNMA1_03_CpG_4.5 | .02261 | 40.04 (12.16–73.76) | 37.93 (20.69–57.74) |
| ECRG4_001_CpG_42 | .03367 | 60.21 (26.24–87.84) | 64.06 (42.52–82.03) |
| FLNC_002_CpG_28.29.30.31 | .03877 | 33.33 (7.49–70.07) | 31.25 (16.12–50.01) |
| ECRG4_001_CpG_43 | .04627 | 70.02 (34.75–93.33) | 66.67 (46.04–83.48) |
| Mrp score | |||
| All recurrence | .00069 | 71.12 (52.02–85.5) | 71.90 (53.22–86.24) |
| Local recurrence | .00156 | 80.32 (44.04–97.5) | 81.20 (63.62–92.82) |
| Systemic recurrence | .02035 | 72.72 (39.03–94.02) | 75.14 (56.66–88.52) |
| PSA recurrence | .33745 | 60.26 (26.02–87.80) | 59.42 (40.64–76.36) |
All the recurrence groups including PSA (n = 10), local (n = 10), and systemic (n = 12) recurrences were compared with the nonrecurrence group (n = 32). Sensitivity and specificity of the Mrp score is shown for overall recurrence prediction, local, systemic, and PSA recurrences.